After months of rumous, Audi has unveiled a new EV range in China, sporting, instead of the rings (arguably one of the best ...

The U.S. Centers for Disease Control and Prevention decided, opens new tab to hold off recommending the use of the vaccine, Arexvy, in adults under 60, despite the Food and Drug Administration ...

In its update posted this morning, GSK revealed that sales of its Arexvy vaccine came in at £1.24 billion ($1.57 billion) in 2023, including £529 million ($671 million) from the fourth quarter.

GSK’s data with Arexvy, from the AReSVi-006 trial, appeared to show slightly higher efficacy, with the caveat that comparing results from studies with different protocols is challenging.

Moderna MRNA is set to report third-quarter 2024 earnings on Nov. 7, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $1.25 billion and a loss of $1.91 per ...

Reuters is an international news organisation owned by Thomson Reuters GSK has received Canadian approval for Arexvy, its respiratory syncytial virus vaccine in adults between 50 and 59 ...

GSK’s (LSE: GSK) Arexvy (RSV vaccine) has received an expanded approval in Canada to prevent lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults aged 50-59 who are at ...

One year after reports of supply chain issues, 49% of reports in the US and 34% of reports in Canada were associated with drug shortages. Board Chairman Kelly Aberasturi told the AP that while he ...

The vaccine was previously approved in Canada for adults aged 60 and over. Credit: MargJohnsonVA/Shutterstock. GlaxoSmithKline (GSK) has received approval for its ...

The newly approved vaccine, known as Arexvy, represents an advance in preventive health measures, addressing a significant adult demographic at risk from RSV complications. With this approval, Canada ...